» Articles » PMID: 24960177

Long-term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in Db/db Mice

Overview
Journal PLoS One
Date 2014 Jun 25
PMID 24960177
Citations 134
Authors
Affiliations
Soon will be listed here.
Abstract

Inhibition of sodium glucose cotransporter 2 (SGLT2) has been reported as a new therapeutic strategy for treating diabetes. However, the effect of SGLT2 inhibitors on the kidney is unknown. In addition, whether SGLT2 inhibitors have an anti-inflammatory or antioxidative stress effect is still unclear. In this study, to resolve these issues, we evaluated the effects of the SGLT2 inhibitor, dapagliflozin, using a mouse model of type 2 diabetes and cultured proximal tubular epithelial (mProx24) cells. Male db/db mice were administered 0.1 or 1.0 mg/kg of dapagliflozin for 12 weeks. Body weight, blood pressure, blood glucose, hemoglobin A1c, albuminuria and creatinine clearance were measured. Mesangial matrix accumulation and interstitial fibrosis in the kidney and pancreatic β-cell mass were evaluated by histological analysis. Furthermore, gene expression of inflammatory mediators, such as osteopontin, monocyte chemoattractant protein-1 and transforming growth factor-β, was evaluated by quantitative reverse transcriptase-PCR. In addition, oxidative stress was evaluated by dihydroethidium and NADPH oxidase 4 staining. Administration of 0.1 or 1.0 mg/kg of dapagliflozin ameliorated hyperglycemia, β-cell damage and albuminuria in db/db mice. Serum creatinine, creatinine clearance and blood pressure were not affected by administration of dapagliflozin, but glomerular mesangial expansion and interstitial fibrosis were suppressed in a dose-dependent manner. Dapagliflozin treatment markedly decreased macrophage infiltration and the gene expression of inflammation and oxidative stress in the kidney of db/db mice. Moreover, dapagliflozin suppressed the high-glucose-induced gene expression of inflammatory cytokines and oxidative stress in cultured mProx24 cells. These data suggest that dapagliflozin ameliorates diabetic nephropathy by improving hyperglycemia along with inhibiting inflammation and oxidative stress.

Citing Articles

Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology.

Gaggini M, Sabatino L, Suman A, Chatzianagnostou K, Vassalle C Cells. 2025; 14(5).

PMID: 40072115 PMC: 11898734. DOI: 10.3390/cells14050387.


Targeting Ferroptosis in Parkinson's: Repurposing Diabetes Drugs as a Promising Treatment.

Duta C, Muscurel C, Dogaru C, Stoian I Int J Mol Sci. 2025; 26(4).

PMID: 40003982 PMC: 11855881. DOI: 10.3390/ijms26041516.


Dapagliflozin exerts anti-apoptotic effects by mitigating macrophage polarization modulation of the phosphoinositide 3-kinase/protein kinase B signaling pathway.

Xiong S, Huang L, Liu H, Zhang X, Li M, Cui Y World J Diabetes. 2025; 16(2):97287.

PMID: 39959262 PMC: 11718488. DOI: 10.4239/wjd.v16.i2.97287.


Exploring the Role of SGLT2 Inhibitors in Cancer: Mechanisms of Action and Therapeutic Opportunities.

Pandey A, Alcaraz Jr M, Saggese P, Soto A, Gomez E, Jaldu S Cancers (Basel). 2025; 17(3).

PMID: 39941833 PMC: 11815934. DOI: 10.3390/cancers17030466.


Sodium-Glucose-Cotransporter-2 Inhibitor Therapy and Intermitted Fasting in Cardiorenal Syndrome: The Role of Glucose-Mediated Oxidative Stress.

Schroder K J Clin Med. 2025; 14(3).

PMID: 39941418 PMC: 11818847. DOI: 10.3390/jcm14030746.


References
1.
Okada S, Shikata K, Matsuda M, Ogawa D, Usui H, Kido Y . Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes. 2003; 52(10):2586-93. DOI: 10.2337/diabetes.52.10.2586. View

2.
Chen L, Leung P . Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus. Diabetes Obes Metab. 2013; 15(5):392-402. DOI: 10.1111/dom.12064. View

3.
Wright E . Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol. 2001; 280(1):F10-8. DOI: 10.1152/ajprenal.2001.280.1.F10. View

4.
Kodera R, Shikata K, Kataoka H, Takatsuka T, Miyamoto S, Sasaki M . Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia. 2011; 54(4):965-78. DOI: 10.1007/s00125-010-2028-x. View

5.
Navarro-Gonzalez J, Mora-Fernandez C, de Fuentes M, Garcia-Perez J . Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2011; 7(6):327-40. DOI: 10.1038/nrneph.2011.51. View